EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genotype–Phenotype-Guided Personalization of Azathioprine Therapy in Autoimmune Hepatitis: Real World Data from Clinical Practice

Judit Julian, Ignasi Olivas, Ana Lizana, Pinelopi Arvaniti, Sergio Rodríguez-Tajes, Helena Hernández-Évole, Ana Pascual-Dapena, Jaime Sainz de Medrano, Mercè Brunet, Maria-Carlota Londoño

Pharmaceuticals · 16.11.2026 · 19 (11) · 1821

DOI: 10.3390/ph19111821 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 16.11.2026. Verfasst von Judit Julian und 9 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Hospital Clínic Barcelona, Societat Catalana de Digestologia.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Azathioprine (AZA) remains a key maintenance therapy in autoimmune hepatitis (AIH), but the role of pharmacogenetic testing and thiopurine metabolite monitoring in routine clinical practice is not fully established. We aimed to characterize thiopurine metabolite profiles according to biochemical response and TPMT genotype and to assess how therapeutic drug monitoring (TDM) informs treatment decisions in adults with AIH.

Methods

We conducted a retrospective single-center observational study including adults with probable or definite AIH treated with AZA and with at least one erythrocyte 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) measurement. Complete biochemical response (CBR) was defined as the normalization of transaminases and IgG. TPMT genotyping was performed according to local practice.

Results

Among 112 patients (67% female; median age 55 years), TPMT genotype was available in 96, including seven (7.3%) TPMT*1/3A heterozygotes. Heterozygotes had higher 6-TGN concentrations and virtually undetectable 6-MMP despite lower AZA doses. The median 6-TGN was 386 pmol/8 × 108 RBC. AZA dose and TPMT*1/*3A genotype were independently associated with higher 6-TGN concentrations (β = +77 pmol/8 × 108 RBC per 0.5 mg/kg/day, p = 0.035; and β = +290 pmol/8 × 108 RBC, p = 0.004, respectively). Single-point 6-TGN concentrations were not associated with CBR. TDM was followed by treatment modification in 38 patients (34%), including dose adjustment, treatment switching, or the identification of non-adherence. No AZA-related myelotoxicity was identified.

Conclusions

Single-point 6-TGN concentrations did not discriminate biochemical response, supporting interpretation in a clinical context rather than reliance on fixed thresholds. TDM provided clinically actionable information, while TPMT genotype identified a distinct metabolite profile associated with higher 6-TGN exposure at lower AZA doses. Together, these data support individualized interpretation of pharmacogenetic and metabolite information in AIH.

Förderung

  • Instituto de Salud Carlos III
  • Hospital Clínic Barcelona
  • Societat Catalana de Digestologia

Zitieren

APA

Julian, J., Olivas, I., Lizana, A., Arvaniti, P., Rodríguez-Tajes, S., Hernández-Évole, H., Pascual-Dapena, A., Medrano, J. S. D., Brunet, M., & Londoño, M. (2026). Genotype–Phenotype-Guided Personalization of Azathioprine Therapy in Autoimmune Hepatitis: Real World Data from Clinical Practice. Pharmaceuticals, 19(11), 1821. https://doi.org/10.3390/ph19111821

Vancouver

Julian J, Olivas I, Lizana A, Arvaniti P, Rodríguez-Tajes S, Hernández-Évole H, et al. Genotype–Phenotype-Guided Personalization of Azathioprine Therapy in Autoimmune Hepatitis: Real World Data from Clinical Practice. Pharmaceuticals. 2026;19(11):1821. doi:10.3390/ph19111821

BibTeX
@article{Julian2026,
  author = {Julian, Judit and Olivas, Ignasi and Lizana, Ana and Arvaniti, Pinelopi and Rodríguez-Tajes, Sergio and Hernández-Évole, Helena and Pascual-Dapena, Ana and Medrano, Jaime Sainz de and Brunet, Mercè and Londoño, Maria-Carlota},
  title = {Genotype–Phenotype-Guided Personalization of Azathioprine Therapy in Autoimmune Hepatitis: Real World Data from Clinical Practice},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1821},
  doi = {10.3390/ph19111821}
}
Kostenlos starten →